ClinicalTrials.gg
CompletedNCT01802411Updated Jul 12, 2021Results posted

Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy

A Phase 3 interventional study of EXPAREL 266 mg and Placebo in Posterolateral Thoracotomy and Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-12.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Enrollment
12th of 93
191 · median 80
Started
2012
with 5 others
Phase 3
11 of 93
none open now
Registered
3rd of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 12th largest by enrollment, is one of 6 that started in 2012, is one of 11 in phase 3, and was the 3rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.

03

Conditions studied

  • Posterolateral Thoracotomy
  • Postoperative Pain

Browse trials for

Keywords

  • liposome bupivacaine
  • posterolateral thoracotomy
  • intercostal nerve block
  • postoperative pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ≥18 years of age.
  • Scheduled to undergo a thoracotomy of at least 3 inches (7.6 cm) of intercostal incisional length or requiring insertion of an inter-rib spreader/retractor for a primary thoracic non-infectious indication under general anesthesia.
  • (ASA) Physical Status 1 - 3.
  • Able to provide , adhere to the study visit schedule, and complete all study assessments.
  • Able to demonstrate sensory function by exhibiting sensitivity to cold in one dermatome area in which study drug will be administered.

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration. Female subjects must be surgically sterile, at least 2 years menopausal, or using an acceptable method of . If of , must have a documented negative pregnancy test within 24 hours before surgery.
  • Any planned pleurodesis as part of the surgical procedure.
  • Use of any of the following medications within the times specified before surgery: long-acting opioid medication, non-steroidal anti-inflammatory drug (NSAID), or aspirin (except for low-dose aspirin used for cardioprotection or acetaminophen/paracetamol) within 3 days and any opioid medication within 24 hours.
  • Use of selective serotonin reuptake inhibitors (SSRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®) within 3 days of surgery.
  • Concurrent painful physical condition or concurrent surgery that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the surgery, and which may confound the postsurgical assessments (e.g., cancer pain, chronic neuropathic pain, concurrent abdominal surgery).
  • Current use of systemic glucocorticosteroids within 1 month of enrollment.
  • Body weight \< 50 kilograms (110 pounds) or a ≥ 35 kg/m2.
  • to any of the pain-control agents planned for surgical or postsurgical use (i.e., fentanyl, morphine, hydromorphone, oxycodone, or bupivacaine).
  • Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  • Previous participation in a liposome bupivacaine study.
  • History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  • Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, could interfere with study assessments or compliance.
  • Current or historical evidence of any disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postsurgical course or interfere with the determination of pain intensity related solely to the surgery.
  • Significant medical conditions (including widely disseminated disease) or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures.
  • Subjects who are planned to receive Entereg® (alvimopan).
  • Subjects who will receive prophylactic antiemetics or planned postsurgical antiemetics given without regard to the subject's emesis needs.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
191 participants (actual)

Study arms

  • Active comparator
    EXPAREL 266 mg

    Intercostal nerve block using single total administration of 20 mL EXPAREL (bupivacaine liposome injectable suspension) 266 mg (approximately 88 mg \[6.6 mL\] to each of three nerve segments)

    Drug: EXPAREL 266 mg

  • Placebo comparator
    Placebo

    Intercostal nerve block using single total administration of 20 mL normal saline (6.6 mL to each of three nerve segments)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours

    AUC of pain intensity scores at rest through 72 hours postsurgery. Participants assumed a resting position that did not exacerbate his or her postsurgical pain. Pain intensity scores were measured at baseline and 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours postsurgery, at first request for rescue pain medication, and on day 12 using the numeric rating scale at rest (NRS-R; 0=no pain and 10=worst possible pain).

    Time frame: 0-72 hours postsurgery

Secondary outcomes

  1. Total Postsurgical Opioid Consumption Through 72 Hours

    Total postsurgical opioid consumption (morphine equivalent) through 72 hours postsurgery

    Time frame: 0-72 hours postsurgery

  2. Time to First Opioid Rescue Through 72 Hours Postsurgery

    Time to first use of opioid rescue medication through 72 hours postsurgery, calculated as the date and time of first opioid use minus the date and time of the end of surgery.

    Time frame: 72 hours postsurgery

07

Results

Posted Dec 9, 2020
Limitations and caveats
Study drug delivery to the intercostal nerve via instillation, not US-guided injection, likely prevented optimal placement/retention, as supported by pharmacokinetic data. Thus, efficacy of study drug as regional nerve block could not be meaningfully evaluated.

Participant flow

Participant flow — Overall Study
MilestoneEXPAREL 266 mgPlacebo
Started9695
Completed8274
Not completed1421
Withdrew: Death21
Withdrew: Adverse event27
Withdrew: Lack of efficacy810
Withdrew: Withdrawal by subject02
Withdrew: Planned pleurodesis as part of the proc10
Withdrew: Surgery aborted after bronchoscopy10
Withdrew: Proc changed to video-asst thorascopic01

Outcome measures

PrimaryArea Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours

AUC of pain intensity scores at rest through 72 hours postsurgery. Participants assumed a resting position that did not exacerbate his or her postsurgical pain. Pain intensity scores were measured at baseline and 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours postsurgery, at first request for rescue pain medication, and on day 12 using the numeric rating scale at rest (NRS-R; 0=no pain and 10=worst possible pain).

Time frame:
0-72 hours postsurgery
Reported as:
Least squares mean · score on a scale * hr
Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours
score on a scale * hrEXPAREL 266 mgPlacebo
Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours472.1 ± 37.19459.0 ± 36.57
Statistical analysis
  • EXPAREL 266 mg vs Placebo · ANCOVA · p = 0.5598 · Lsmd: 13.1 · 95% CI -31 to 57
SecondaryTotal Postsurgical Opioid Consumption Through 72 Hours

Total postsurgical opioid consumption (morphine equivalent) through 72 hours postsurgery

Time frame:
0-72 hours postsurgery
Reported as:
Mean · mg morphine equivalent dose
Total Postsurgical Opioid Consumption Through 72 Hours
mg morphine equivalent doseEXPAREL 266 mgPlacebo
Total Postsurgical Opioid Consumption Through 72 Hours70.88 ± 37.53771.38 ± 39.418
SecondaryTime to First Opioid Rescue Through 72 Hours Postsurgery

Time to first use of opioid rescue medication through 72 hours postsurgery, calculated as the date and time of first opioid use minus the date and time of the end of surgery.

Time frame:
72 hours postsurgery
Reported as:
Median · hours
Time to First Opioid Rescue Through 72 Hours Postsurgery
hoursEXPAREL 266 mgPlacebo
Time to First Opioid Rescue Through 72 Hours Postsurgery1.1 (0.08 to 72.00)0.7 (0.10 to 72.00)

Adverse events

Collected over From time of randomization through the day 30 follow-up contact. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL 266 mg2/94 (2.1%)12/94 (12.8%)63/94 (67%)
Placebo4/91 (4.4%)10/91 (11%)55/91 (60.4%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventEXPAREL 266 mgPlacebo
Cardiac ArrestCardiac disorders2/942/91
PneumothoraxRespiratory, thoracic and mediastinal disorders2/942/91
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/942/91
Myocardial infarctionCardiac disorders2/941/91
Atrial fibrillationCardiac disorders0/941/91
Respiratory failureRespiratory, thoracic and mediastinal disorders0/941/91
PneumoniaInfections and infestations1/941/91
SepsisInfections and infestations1/941/91
Lobar pneumoniaInfections and infestations0/941/91
Lung infection PseudomonalInfections and infestations0/941/91
Most frequent other events
Showing 10 of 11
Most frequent other events
EventEXPAREL 266 mgPlacebo
PyrexiaGeneral disorders16/9412/91
HypertensionVascular disorders10/945/91
NauseaGastrointestinal disorders9/947/91
VomitingGastrointestinal disorders9/948/91
FatigueGeneral disorders9/944/91
ConstipationGastrointestinal disorders7/944/91
Confusional statePsychiatric disorders7/944/91
DysgeusiaNervous system disorders7/942/91
Atrial fibrillationCardiac disorders2/946/91
HypotensionVascular disorders2/946/91

Baseline characteristics

Baseline characteristics were analyzed in the safety population, which included all participants who received study drug, with analysis based on actual treatment received. Six randomized participants (2 in the EXPAREL 266 mg group and 4 in the placebo group) did not receive study drug and were excluded from the safety population.

Age, Continuous
Age, Continuous(years)EXPAREL 266 mgPlaceboTotal
Mean57.9 ± 12.7158.5 ± 13.0358.2 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL 266 mgPlaceboTotal
Female303161
Male6460124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EXPAREL 266 mgPlaceboTotal
Hispanic or Latino437
Not Hispanic or Latino9088178
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EXPAREL 266 mgPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9491185
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)EXPAREL 266 mgPlaceboTotal
United States235
Poland383270
Bulgaria202848
Czechia171835
Georgia171027
American Society of Anesthesiologists (ASA) classification
American Society of Anesthesiologists (ASA) classification(Participants)EXPAREL 266 mgPlaceboTotal
1322456
2485098
3141731
08

Study locations

21 sites
  • Jackson Memorial Hospital/University of Miami, 1611 NW 12th Avenue (R-C300)
    Miami, Florida 33136, United States
  • Louisiana State University Health Sciences Center - Shreveport, 1501 Kings Hwy
    Shreveport, Louisiana 71103, United States
  • Sanford Heart Center 801 Broadway North
    Fargo, North Dakota 58122, United States
  • Research Concepts, GP, LLC, 4525 Texas St.
    Bellaire, Texas 77401, United States
  • UT Southwestern Medical Center, Dept. Cardiovas7726cular & Thoracic Surgery, 5909 Harry Hines Blvd., 9th Fl.
    Dallas, Texas 75390-8879, United States
  • The Methodist Hospital UANEU25, Department of Cardiovascular Surgery, 6550 Fannin, Suite 1401
    Houston, Texas 77030, United States
  • MultiCare Health System dba Tacoma General Hospital 315 Martin Luther King Jr Way
    Tacoma, Washington 98405, United States
  • Thoracic Surgery Clinic, SHATPulmD 'Sveta Sofia'
    Plovdiv, Bulgaria
  • Department of surgery with activity in thoracic surgery
    Sofia, Bulgaria
  • Military Medical Academy
    Sofia, Bulgaria
  • University Multiprofile Hospiatl for Active Treatment and Emergency Medicine 'Pirogov'
    Sofia, Bulgaria
  • Krajska nemocnice Liberec, a.s., Vseobecna chirurgie
    Liberec, Czechia
  • Fakultni nemocnice Olomouc I. chirurgicka klinika
    Olomouc, Czechia
  • Thomayerova nemocnice Oddeleni hrudni chirurgie Videnska
    Prague, Czechia
  • Amtel Hospital First Clinical' LLC
    Tbilisi, Georgia
  • Jsc 'National Center for Tuberculosis and Lung Diseases'/
    Tbilisi, Georgia
  • Jsc 'National Center for Tuberculosis and Lung Diseases'
    Tbilisi, Georgia
  • Klinika Chirurgii Klatki Piersiowej Pomorskiego Uniwersytetu Medycznego w Szczecinie Specjalistyczny Szpital im. prof. Alfreda Sokolowskiego
    Szczecin, Poland
  • Oddzial Zabiegowy Kliniki Nowotworow Pluca i Klatki Piersiowej Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie
    Warszawa, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko Slaskiego UM w Katowicach Klinika Anestezjologii i Intensywnej Terapii
    Zabrze, Poland
  • Klinika Chirurgii Klatki Piersiowej, Chirurgii Ogolnej i Onkologicznej Uniwersytecki Szpital Kliniczny
    Łódź, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2020, 7 years 6 months after primary completion. A results delay was requested in Oct 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2013
First posted
Mar 1, 2013
Start
Dec 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results delay requested
Oct 9, 2013
Results first posted
Dec 9, 2020
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01802411
Responsible party
Sponsor
First posted
Mar 1, 2013
Start date
Dec 2012
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Dec 9, 2020
Last update
Jul 12, 2021

Study contacts

Erol Onel, MD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion